These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 17671156)

  • 41. Mirk/dyrk1B kinase is upregulated following inhibition of mTOR.
    Deng X; Hu J; Ewton DZ; Friedman E
    Carcinogenesis; 2014 Sep; 35(9):1968-76. PubMed ID: 24590896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of rational drug combinations with investigational targeted agents.
    Clark A; Ellis M; Erlichman C; Lutzker S; Zwiebel J
    Oncologist; 2010; 15(5):496-9. PubMed ID: 20489187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.
    Gao J; Zheng Z; Rawal B; Schell MJ; Bepler G; Haura EB
    Cancer Biol Ther; 2009 Sep; 8(17):1671-9. PubMed ID: 19633423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
    Seiwert TY; Jagadeeswaran R; Faoro L; Janamanchi V; Nallasura V; El Dinali M; Yala S; Kanteti R; Cohen EE; Lingen MW; Martin L; Krishnaswamy S; Klein-Szanto A; Christensen JG; Vokes EE; Salgia R
    Cancer Res; 2009 Apr; 69(7):3021-31. PubMed ID: 19318576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
    Engelman JA; Chen L; Tan X; Crosby K; Guimaraes AR; Upadhyay R; Maira M; McNamara K; Perera SA; Song Y; Chirieac LR; Kaur R; Lightbown A; Simendinger J; Li T; Padera RF; García-Echeverría C; Weissleder R; Mahmood U; Cantley LC; Wong KK
    Nat Med; 2008 Dec; 14(12):1351-6. PubMed ID: 19029981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PI3K pathway alterations in cancer: variations on a theme.
    Yuan TL; Cantley LC
    Oncogene; 2008 Sep; 27(41):5497-510. PubMed ID: 18794884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
    Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
    J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
    Burris HA
    Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
    Wee S; Lengauer C; Wiederschain D
    Curr Opin Oncol; 2008 Jan; 20(1):77-82. PubMed ID: 18043260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
    Engelman JA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4637-40. PubMed ID: 17671156
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
    Herbst RS; Oh Y; Wagle A; Lahn M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J; Herbst RS; Onn A
    Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.